NASDAQ · STOCK
HCA Healthcare
$406.56
52W $330.00 – $556.52
58/100
$90.73B
13.2
1.11
Price History (6M)
Executive Summary
5 analysts weighed in with 60% agreement on a bullish lean. Portfolio Manager: Portfolio position concentration is currently healthy. Growth Analyst: Growth rate is decelerating quarter over quarter -- the trend line matters more than the level. Overall recommendation: BUY.
Bull & Bear Case
Bull Case
- Positive MACD histogram signals bullish momentum.
- Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 12.2% downside vs 2.6% upside.
AI Investment Committee
Committee Consensus
As of July 11, 2026
Overall Committee Score
58/100
Agreement
43%
Analysts
7
Conviction
Contested
Growth Analyst
bearish
35
/ 100 · Low confidence
Growth story is weak, decelerating, or inconsistent
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ MACD histogram positive -- bullish momentum
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
neutral
60
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bullish
75
/ 100 · Low confidence
The existing book is healthy enough that position-sizing here is a matter of stock selection, not portfolio constraints
+ Portfolio position concentration is currently healthy
Technical Analysis
RSI (14)
56.6
Neutral
MACD Histogram
3.629
Bullish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Lh Ll
Support
$356.89
Resistance
$417.02
Bollinger %B
0.72
Inside Bands
Price vs Moving Averages
EMA 9
$405.53
Above
EMA 21
$398.86
Above
EMA 50
$408.71
Below
EMA 200
$435.61
Below
Fundamental Analysis
Valuation
50
Growth
62
Profitability
86
Financial Health
7
Valuation
P/E Ratio
13.2×
P/B Ratio
97.29×
PEG Ratio
—
Dividend Yield
0.76%
52W High
$556.52
52W Low
$330.00
Quality & Growth
ROE
—
ROA
1126.0%
Gross Margin
8500.0%
Operating Margin
1567.0%
Revenue Growth YoY
+671.0%
Debt / Equity
54.20
AI Fundamental Assessment
P/E ratio of 13.2 (inexpensive relative to a 15-40x range); Price-to-book of 97.3x; Revenue growth (YoY) of 6.7%; EPS growth (YoY) of 29.2%; Return on equity of 695.7%; Return on assets of 11.3%; Net margin of 8.9%; Gross margin of 85.0%; Current ratio of 0.97 (tight short-term liquidity); Debt-to-equity of 54.20; Most recent quarter missed estimates by 0.8%; EPS growth decelerating (+17.0% -> -12.2% QoQ); Analyst estimates rising over recent quarters
Key Risks
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 12.2% downside vs 2.6% upside.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full HCA Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Mobile